What is CellFE?
CellFE is at the forefront of revolutionizing cell therapy production through its proprietary microfluidic-based gene editing technology. The company's flagship products, such as the Ryva Mechanoporation System, are engineered to empower researchers and developers in the cell therapy field, facilitating the creation of more affordable and accessible life-saving treatments. By tackling the critical challenges of scalability and cost in cell therapy development, CellFE is dedicated to enhancing global access to advanced therapeutic solutions and supporting innovators in bringing superior treatments to patients worldwide.
How much funding has CellFE raised?
CellFE has raised a total of $22M across 1 funding round:
Series A
$22M
Series A (2023): $22M with participation from Merck Ventures, Dynamk Capital, and Cota Capital
Key Investors in CellFE
Merck Ventures
Merck Ventures is the strategic venture capital arm of Merck, focused on investing in innovative technologies that can significantly impact the company's core business areas. They actively support portfolio companies in translating innovation into commercial success, with a strong emphasis on early-stage investments.
Dynamk Capital
Dynamk Capital is a venture capital firm specializing in life science industrials, including tools, technologies, and services crucial for the development and production of therapies. They aim to support innovative companies advancing the life sciences sector.
Cota Capital
Cota Capital focuses on early-stage technology companies addressing innovative challenges in the enterprise sector, combining financial investment with deep operational expertise to foster transformative businesses.
What's next for CellFE?
The substantial enterprise-level funding and recent strategic investment position CellFE for accelerated growth and market expansion. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. CellFE's focus on innovation in gene editing and microfluidics suggests a strategic trajectory aimed at solidifying its leadership in the cell therapy manufacturing space, potentially leading to new product development and strategic partnerships to further democratize access to advanced therapies.
See full CellFE company page
